<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Science and Innovations in Medicine</journal-id><journal-title-group><journal-title xml:lang="en">Science and Innovations in Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Наука и инновации в медицине</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2500-1388</issn><issn publication-format="electronic">2618-754X</issn><publisher><publisher-name xml:lang="en">FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">43796</article-id><article-id pub-id-type="doi">10.35693/2500-1388-2020-5-2-88-92</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Cardiology</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Кардиология</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Indicators of humoral regulation of the circulatory system in obese patients</article-title><trans-title-group xml:lang="ru"><trans-title>Показатели гуморальной регуляции системы кровообращения у больных с ожирением</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3492-1778</contrib-id><name-alternatives><name xml:lang="en"><surname>Zaletova</surname><given-names>Tatyana S.</given-names></name><name xml:lang="ru"><surname>Залетова</surname><given-names>Татьяна Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>researcher, Department of Personalized therapy and dietetics</p></bio><bio xml:lang="ru"><p>научный сотрудник отделения персонализированной терапии и диетологии</p></bio><email>Tatyana.zaletova@ya.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1876-1230</contrib-id><name-alternatives><name xml:lang="en"><surname>Derbeneva</surname><given-names>Svetlana A.</given-names></name><name xml:lang="ru"><surname>Дербенева</surname><given-names>С. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, Senior researcher, Department of Cardiovascular pathology</p></bio><bio xml:lang="ru"><p>к.м.н., старший научный сотрудник отделения сердечно-сосудистой патологии</p></bio><email>Tatyana.zaletova@ya.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6271-7037</contrib-id><name-alternatives><name xml:lang="en"><surname>Feofanova</surname><given-names>Tatyana B.</given-names></name><name xml:lang="ru"><surname>Феофанова</surname><given-names>Т. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, researcher, Department of Personalized therapy and dietetics</p></bio><bio xml:lang="ru"><p>научный сотрудник отделения персонализированной терапии и диетологии</p></bio><email>Tatyana.zaletova@ya.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4616-1825</contrib-id><name-alternatives><name xml:lang="en"><surname>Katsuba</surname><given-names>Andrei A.</given-names></name><name xml:lang="ru"><surname>Кацуба</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>resident of the Department of Cardiovascular pathology</p></bio><bio xml:lang="ru"><p>ординатор отделения сердечно-сосудистой патологии</p></bio><email>Tatyana.zaletova@ya.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Federal research center of nutrition, biotechnology and food safety</institution></aff><aff><institution xml:lang="ru">ФГБУН «Федеральный исследовательский центр питания, биотехнологии и безопасности пищи»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-06-15" publication-format="electronic"><day>15</day><month>06</month><year>2020</year></pub-date><volume>5</volume><issue>2</issue><issue-title xml:lang="en">VOL 5, NO2 (2020)</issue-title><issue-title xml:lang="ru">ТОМ 5, №2 (2020)</issue-title><fpage>88</fpage><lpage>92</lpage><history><date date-type="received" iso-8601-date="2020-09-08"><day>08</day><month>09</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Zaletova T.S., Derbeneva S.A., Feofanova T.B., Katsuba A.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, Залетова Т.С., Дербенева С.А., Феофанова Т.Б., Кацуба А.А.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Zaletova T.S., Derbeneva S.A., Feofanova T.B., Katsuba A.A.</copyright-holder><copyright-holder xml:lang="ru">Залетова Т.С., Дербенева С.А., Феофанова Т.Б., Кацуба А.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://innoscience.ru/2500-1388/article/view/43796">https://innoscience.ru/2500-1388/article/view/43796</self-uri><abstract xml:lang="en"><p><bold>Objectives </bold>– to study the indicators of humoral regulation of circulatory system in obese patients as the predictors of CHF development.</p> <p><bold>Materials and methods.</bold> Two groups of 40 patients were formed: the first group consisted of patients with I or II grades obesity with BMI of up to 40 kg/m<sup>2</sup>, the second group included patients with grade III obesity with BMI of over 40 kg/m<sup>2</sup>. None of the selected patients had a history of cardiovascular events. The concentration value of renin-angiotensin-aldosterone system components and level of N-terminal pro B-type natriuretic peptide (NT-pro-BNP) was determined.</p> <p><bold>Results.</bold> Aldosterone level in grade I–II obese patients was close to normal upper border: 58.9 [54.9; 73.8] pg/ml (normal range is 10–60 pg/ml), while in patients with grade III obesity it was 79.5 [64.5; 90.1], which is 25.9% higher than in patients of the first group and 24.5% higher above the normal level (p &lt; 0.05). These two groups was significantly different not only in average plasma aldosterone level, but in absolute number of patients with hyperaldosteronism, whose number accounted for 46.2% in grades I or II obese patients and 85.7% among patients with grade III obesity. Plasma renin level and angiotensin II levels in both groups was within the normal range. NT-proBNP level in the first group was 23.7 [10.6; 23.6] pg/ml, in the second group – 138.0 [121.5; 145.9] pg/ml, which is 5.8 times higher (p = 0.001). In both groups of patients, the correlation analysis showed that aldosterone and NT-proBNP levels are closely related (r = 0.74, p &lt; 0.05).</p> <p><bold>Conclusion. </bold>This study suggests that aldosterone level can be used as a predictor of HF.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель </bold>– исследовать показатели гуморальной регуляции кровообращения у пациентов с ожирением как предикторов развития ХСН.</p> <p><bold>Материал и методы.</bold> Было проведено обследование двух групп по 40 пациентов: группа 1 – пациенты с индексом массы тела до 40 кг/м<sup>2</sup> (ожирение I–II степени), группа 2 – пациенты с индексом массы тела свыше 40 кг/м<sup>2</sup> (ожирение III степени), в анамнезе которых отсутствуют сердечно-сосудистые события. Исследование проводилось путем определения концентрации компонентов ренин-ангиотензин-альдостероновой системы, а также определения уровня N-концевого предшественника мозгового натрийуретического пептида (NT-pro-BNP).</p> <p><bold>Результаты.</bold> Концентрация альдостерона в крови пациентов из первой группы составила 58,9 [54,9; 73,8] пг/мл, что соответствует верхней границе нормы (10–60 пг/мл). Во второй группе концентрация альдостерона составила 79,5 [64,5; 90,1] пг/мл, что превышает показатели первой группы пациентов на 25,9% и на 24,5% – норму (при р&lt;0,05). Статистически значимые различия были получены как по средним значениям концентрации альдостерона плазмы, так и по абсолютному количеству пациентов, показатели альдостерона плазмы которых превышало норму. Доля таких пациентов составила 46,2% в первой группе (ожирение I–II степени) и 85,7% среди пациентов второй группы (ожирение III степени). Вместе с тем концентрации ангиотензина II и ренина не превышала норму в обеих исследуемых группах. Концентрация NT-proBNP для пациентов из первой группы составляла 23,7 [10,6; 23,6] пг/мл, для пациентов из второй группы аналогичный показатель составил 138,0 [121,5; 145,9] пг/мл. Расчет корреляционных связей показывает тесную корреляцию концентраций альдостерона с концентрацией NT-proBNP (r=0,74, р&lt;0,05) для обеих групп пациентов.</p> <p><bold>Заключение.</bold> Концентрацию альдостерона плазмы можно считать предиктором СН.</p></trans-abstract><kwd-group xml:lang="en"><kwd>renin-angiotensin-aldosterone system</kwd><kwd>aldosterone</kwd><kwd>heart failure</kwd><kwd>obesity</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ренин-ангиотензин-альдостероновая система</kwd><kwd>альдостерон</kwd><kwd>сердечная недостаточность</kwd><kwd>ожирение</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Arutyunov GP. Therapy of heart failure. Is the choice of the first drug always determined? Russkiy meditsinskiy zhurnal. 2006;2:137–142. (In Russ.). [Арутюнов Г.П. Терапия ХСН. Всегда ли детерминирован выбор первого препарата? Русский медицинский журнал. 2006;2:137–142].</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Vogt B, Bochud M, Burnier M. The association of aldosterone with obesity-related hypertension and the metabolic syndrome. Seminars in nephrology. 2007;27(5):529–537. doi: 10.1016/j.semnephrol.2007.07.009</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Lastra G, Habibi J, Whaley-Connell A, et al. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology. 2009;150(6):2561–2568. doi: 10.1210/en.2008-1391</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Pulakat L, DeMarco V, Ardhanari S, et al. Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities. American journal of physiology-regulatory, integrative and comparative physiology. 2011;301(4):885–895. doi: 10.1152/ajpregu.00316.2011</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Tasic I, Lovic D. Hypertension and cardiometabolic disease. Front Biosci (Schol Ed). 2018;1(10):166–174.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Chen B, Chen X, Liu C, et al. Huang Y Co-expression of Akt1 and Wnt11 promotes the proliferation and cardiac differentiation of mesenchymal stem cells and attenuates hypoxia/reoxygenation-induced cardiomyocyte apoptosis. Biomed Pharmacother. 2018;108:508–514. doi: 10.1016/j.biopha.2018.09.047</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Steinbusch L, Luiken J, Vlasblom R, et al. Absence of fatty acid transporter CD36 protects against Western-type diet-related cardiac dysfunction following pressure overload in mice. American journal of physiology-endocrinology and metabolism. 2011;301(4):618–627. doi: 10.1152/ajpendo.00106.2011</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Zhou X, Ma L, Habibi J, et al. Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the zucker obese rat. Hypertension. 2010;55(4):880–888. doi: 10.1161/hypertensionaha.109.145136</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Malhotra J, Kaufman R. ER Stress and Its Functional Link to Mitochondria: Role in Cell Survival and Death. Cold Spring Harbor Perspectives in Biology. 2011;3(9):004424. doi: 10.1101/cshperspect.a004424</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Chakrabarti A, Chen A, Varner J. A review of the mammalian unfolded protein response. Biotechnology and Bioengineering. 2011;108(12):2777–2793. doi: 10.1002/bit.23282</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Donald F, Behan SHC. Obesity and overweight fact sheet N°311. WHO-2012. Available at: http://www.who.int/mediacentre/factsheets/fs311/en. Accessed 19.02.2020</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Alpert M. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. The American journal of the medical sciences. 2001;321(4);225–236. doi: 10.1097/00000441-200104000-00003</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Dudenbostel T, Ghazi L, Liu M, et al. Body mass index predicts 24-hour urinary aldosterone levels in patients with resistant hypertension. Hypertension. 2016;68(4):995–1003. doi: 10.1161/hypertensionaha.116.07806</mixed-citation></ref></ref-list></back></article>
